DMS Group draws first €4M of €20M EIB facility for next-gen medical imaging R&D
What's the deal? French medical imaging specialist DMS Group has received the first €4M tranche of a €20M financing line from the European Investment Bank (EIB), backed by the EU's InvestEU programme. The funds will accelerate development of next-generation digital radiology, bone densitometry, mobile surgical imaging, and AI-powered image interpretation tools.
The remaining €16M is split into two further tranches — €6M and €10M — available at 18 and 36 months respectively, subject to R&D and regulatory milestones. Each tranche amortises over four years after a two-year deferral, giving a total maturity of six years.
The first tranche carries a fixed 5% annual interest rate, though 3% of that is deferred until maturity. As is standard for EIB innovation financing, the deal includes share subscription warrants (BSA) — 1,205,838 in this case — exercisable at €1.31 per share from May 2032, with a 14-year lifespan running to 2040. Full exercise would dilute existing shareholders by roughly 4.32%.
Why now? DMS Group, listed on Euronext Growth Paris, is gearing up for a product launch cycle stretching from 2026 to 2030. The investment targets new digital X-ray rooms, motorised and non-motorised mobile radiology units, and C-arm systems for operating theatres. The company also plans to expand its production facility in Gallargues-le-Montueux, France, where most spending will occur.
The financing agreement was originally announced in March 2026, and this first drawdown marks the operational start of the programme.
What could go wrong? The remaining tranches are not guaranteed — they hinge on DMS hitting operational, economic, and regulatory milestones. Medical device development timelines are notoriously unpredictable, and any delays could stall access to the larger €10M final tranche.
The warrant structure also introduces future dilution risk. If all BSA A warrants are exercised, a shareholder currently holding 1% of DMS would see that stake drop to about 0.96%. Additional tranches would likely come with further warrants, compounding the dilution.
The signal: The EIB, classified as a government and non-profit investor on Dealroom, has been steadily expanding its role as a direct financier of small-cap European medtech and deep-tech companies — offering structured debt that lets firms like DMS preserve equity at a time when public medtech valuations on Euronext Growth remain subdued. The milestone-gated, warrant-linked structure is becoming the EIB's template for innovation financing, signalling that Brussels views homegrown medical imaging capacity as strategically important enough to underwrite on near-concessional terms.
Read more: hk.marketscreener.com
